Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 12 months [4]. Core Insights - The approval of the clinical trial application (IND) for MRG006A, a novel ADC drug targeting GPC3 for advanced liver cancer, marks a significant advancement in precision treatment for liver cancer [1]. - MRG006A is the first GPC3-targeted ADC to enter clinical trials globally, with GPC3 being highly expressed in 70%-80% of hepatocellular carcinoma cases, making it a promising target for therapy [1]. - The company has a strong pipeline with multiple first-in-class (FIC) drugs and has achieved breakthrough therapy designations for several candidates, positioning it well in the ADC and immunotherapy landscape [4][3]. Financial Projections - Revenue projections for the company are as follows: 368 million RMB in 2024, 944 million RMB in 2025, and 1.428 billion RMB in 2027, with growth rates of 63.2%, 156.5%, and 44.4% respectively [5]. - The net profit attributable to the parent company is expected to improve from a loss of 411 million RMB in 2024 to a profit of 89 million RMB in 2027 [5]. - Earnings per share (EPS) are projected to transition from -0.23 RMB in 2024 to 0.05 RMB in 2027, reflecting a significant turnaround [5]. Product Pipeline and Market Position - The company has a diverse product pipeline that includes two commercialized ADCs and eight candidates in clinical stages, with a focus on unmet clinical needs in liver and pancreatic cancers [3]. - MRG003, the first approved EGFR-targeted ADC in China, and MRG004A for advanced pancreatic cancer are notable products in the pipeline, with ongoing clinical trials [3]. - The company has successfully licensed two ADCs to international partners, indicating strong market potential and a successful "go global" strategy [3].

Investment Rating - The report initiates coverage with a "Buy" rating for Lepu Biopharma (2157.HK) [4] Core Insights - Lepu Biopharma's ADC drug MRG006A has received approval for clinical trials, marking a significant step towards precision treatment for liver cancer [1] - MRG006A is the first GPC3-targeted ADC to enter clinical trials globally, with potential to address unmet clinical needs in liver cancer treatment [1][2] - The company has a strong pipeline with multiple ADC products and has successfully commercialized two drugs, indicating a leading position in the ADC market [3] Financial Projections - Expected revenues for Lepu Biopharma are projected to be 368 million RMB in 2024, 944 million RMB in 2025, and 1.428 billion RMB in 2027, with growth rates of 63.2%, 156.5%, and 44.4% respectively [5] - The net profit attributable to the parent company is forecasted to be -411 million RMB in 2024, -35 million RMB in 2025, and 89 million RMB in 2027, indicating a turnaround by 2027 [5] - Earnings per share (EPS) are expected to improve from -0.23 RMB in 2024 to 0.05 RMB in 2027 [5] Product Pipeline and Market Position - Lepu Biopharma's product pipeline includes 8 clinical candidates, with 6 being ADC products, showcasing a robust focus on innovative therapies [3] - The company has successfully licensed two ADCs internationally, with significant financial agreements, indicating strong market confidence [3] - MRG006A and MRG007 are developed based on the next-generation Hi-TOPi ADC platform, which is expected to enhance the company's value [3]

Company Overview: Lepu Biopharma (2157.HK) Industry Focus - The company operates in the biopharmaceutical industry, specifically focusing on oncology treatments, including immunotherapy, antibody-drug conjugates (ADC), and oncolytic virus therapies [1][2]. Key Points and Arguments R&D Pipeline and Product Development - Lepu Biopharma has developed a comprehensive pipeline of oncology products, covering three major areas: immunotherapy, ADC targeted therapy, and oncolytic virus drugs. The pipeline includes: - Already marketed PD-1 monoclonal antibody, Putilizumab, and MRG003 - Six ADC drugs, one introduced oncolytic virus, and one T cell engager (TCE) drug currently in clinical stages - The company is expected to enter a phase of new drug approvals over the next 3-5 years, indicating a robust pipeline [1][2]. Financial Performance - The company has achieved steady revenue growth driven by business development (BD) and sales, with a stable expense structure. - In the first half of 2025, Lepu Biopharma reported its first profit and positive operating cash flow [2]. Competitive Advantages of ADCs - MRG003 (EGFR ADC) has been approved for use in late-line nasopharyngeal carcinoma (NPC) in China, demonstrating superior survival benefits and safety compared to competitors. The drug is also being positioned for broader indications in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) [2][3]. - MRG004A (TF-ADC) for late-line pancreatic cancer has shown strong competitive potential and is currently in Phase III trials [2][3]. - MRG006A (GPC3 ADC) targets the liver cancer market and has shown promising results in Phase I trials, with plans to initiate Phase III trials in 2026 [3]. Oncolytic Virus Therapy - The company introduced the oncolytic virus therapy CG0070 in 2019, targeting the bladder cancer market. - CG0070 has initiated a rolling Biologics License Application (BLA) with the FDA for high-risk non-muscle invasive bladder cancer (NMIBC) and is undergoing critical registration bridging trials in China. The therapy has demonstrated the best historical durability of efficacy data in the NMIBC field, with a G3+ treatment-related adverse event (TRAE) rate of 0 [3]. International Expansion - The company has made progress in international collaborations with MRG007 (CDH17 ADC) and CTM012 (a tri-antibody targeting CD3/4-1BB/DLL3), enhancing its tumor immunotherapy output [3]. Revenue Projections - Lepu Biopharma is still in the investment phase for new drug development, with projected revenues of 880 million, 1.02 billion, and 1.49 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 138%, 16%, and 47%. The net profit attributable to the parent company is projected to be -20 million, 10 million, and 280 million yuan for the same years [3]. Risks - Potential risks include: - Delays in clinical progress of innovative drugs - Clinical data not meeting expectations - Sales performance of newly launched drugs falling short - Geopolitical risks [4].

Summary of the Conference Call for Lepu Biopharma (2157.HK) Company Overview - Lepu Biopharma is focused on the development of innovative cancer therapies, particularly in the areas of immunotherapy, antibody-drug conjugates (ADC), and oncolytic virus drugs. The company has a robust pipeline and is expected to enter a period of new drug approvals in the next 3-5 years [1][2]. Key Points R&D Pipeline and Drug Approvals - The company has developed multiple oncology product lines, including: - PD-1 monoclonal antibody, Pralsetinib, and MRG003, which are already on the market. - Six ADC drugs, one oncolytic virus, and one T cell engager (TCE) drug currently in clinical stages. - The overall pipeline is well-structured, indicating a promising future for new drug approvals [1][2]. Financial Performance - The company has achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development (BD) and sales efforts [2]. Competitive Advantages of ADCs 1. **MRG003 (EGFR ADC)**: - Approved for use in late-line nasopharyngeal carcinoma (NPC) in China, showing superior survival benefits and safety compared to competitors. - Actively pursuing broader indications in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), with a Phase III trial ongoing for 2L+ HNSCC [2][3]. 2. **MRG004A (TF-ADC)**: - Currently in Phase III trials for late-line pancreatic cancer, demonstrating strong competitive potential [3]. 3. **MRG006A (GPC3 ADC)**: - A first-in-class (FIC) targeting the liver cancer market, with promising results from Phase I trials, and expected to enter Phase III trials in 2026 [3]. 4. **CMG901**: - A global FIC CLDN 18.2 ADC, currently in Phase III trials [3]. 5. **MRG001 (CD20 ADC)**: - Showing potential in diffuse large B-cell lymphoma (DLBCL) [3]. Oncolytic Virus Therapy - The company introduced the oncolytic virus therapy CG0070 in 2019, targeting the bladder cancer market. - CG0070 has initiated a rolling Biologics License Application (BLA) with the FDA for high-risk non-muscle invasive bladder cancer (NMIBC) and is in critical registration bridging trials in China. - Recent Phase III data indicates historical best durability in NMIBC, with a G3+ treatment-related adverse event (TRAE) rate of 0, showcasing both efficacy and safety [3]. International Expansion - The company has successfully collaborated on international projects with MRG007 (CDH17 ADC) and CTM012 (a tri-antibody targeting CD3/4-1BB/DLL3) [3]. Revenue Projections - Revenue forecasts for the company are as follows: - 2025: 880 million CNY - 2026: 1.02 billion CNY - 2027: 1.49 billion CNY - Expected growth rates are 138% in 2025, 16% in 2026, and 47% in 2027, with net profits projected at -20 million CNY in 2025, 10 million CNY in 2026, and 280 million CNY in 2027 [3]. Investment Rating - The company’s ADC pipeline is progressing steadily, and commercial advancements are on track, leading to a "Buy" rating [4]. Risk Factors - Potential risks include: - Delays in clinical progress of innovative drugs. - Subpar clinical data for innovative drugs. - Poor sales performance post-launch of innovative drugs. - Geopolitical risks [4].

Core Viewpoint - The company is entering a new drug approval phase with a well-structured pipeline in oncology, focusing on immunotherapy, ADC targeted therapy, and oncolytic virus drugs, which is expected to yield multiple new drug approvals in the next 3-5 years [1][2]. Pipeline Development - The company has developed multiple oncology products, including two already marketed drugs (PD-1 monoclonal antibody Prutilizumab and MRG003) and has six ADC drugs, one oncolytic virus, and one TCE drug in clinical stages [1]. - MRG003 (EGFR ADC) has been approved for post-line NPC in China, showing superior survival benefits and safety compared to competitors, with ongoing trials for HNSCC and NSCLC [1]. - MRG004A (TF-ADC) for post-line pancreatic cancer is currently in Phase III trials after demonstrating strong competitive advantages in Phase I [2]. - MRG006A (GPC3 ADC) is targeting the liver cancer market, with promising results in Phase I trials and plans to initiate Phase III trials in 2026 [1][2]. Oncolytic Virus Therapy - The company has introduced the oncolytic virus therapy CG0070 for bladder cancer, which is currently undergoing a rolling BLA application with the FDA and is in critical registration bridging trials in China [2]. - CG0070 has shown the best historical durability efficacy data in the NMIBC field, with a G3+TRAE rate of 0, indicating excellent efficacy and safety [2]. Financial Projections - The company is still in the investment phase for innovative drug development, with projected revenues of 880 million, 1.02 billion, and 1.49 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth of 138%, 16%, and 47% [2]. - The net profit attributable to the parent company is expected to be -20 million, 10 million, and 280 million yuan for the same years [2]. Investment Recommendation - The company is rated as a "buy" due to the steady progress of its ADC pipeline and successful commercialization efforts [2].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is entering a new drug approval harvest period with a well-structured pipeline covering ADC (Antibody-Drug Conjugates) and IO (Immuno-Oncology) [3][10]. - The company has multiple oncology product pipelines, including immune therapy, ADC targeted therapy, and oncolytic virus drugs, with several candidates in clinical stages [3][11]. - The company achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development and sales [3][25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, establishing a comprehensive ADC technology platform and has developed multiple ADC products, including PD-1 monoclonal antibody and MRG003 [11][14]. - The pipeline includes six ADC drugs, one oncolytic virus, and one TCE (T-cell Engager) drug in clinical stages, with several candidates entering pivotal trials [14][18]. Unique Features of ADC Candidates - MRG003 (EGFR ADC) has been approved for NPC (Nasopharyngeal Carcinoma) in China, showing superior survival benefits and safety compared to competitors [4][30]. - MRG004A (TF-ADC) is in Phase III trials for pancreatic cancer, while MRG006A (GPC3 ADC) targets the liver cancer market and is expected to enter Phase III trials in 2026 [6][30]. Oncolytic Virus and International Expansion - The company introduced the oncolytic virus therapy CG0070, which is in critical registration trials in China and has shown promising efficacy in the U.S. for bladder cancer [5][30]. - The company has successfully partnered for international expansion with MRG007 (CDH17 ADC) and CTM012 (CD3/4-1BB/DLL3 tri-antibody) [5][30]. Financial Projections and Investment Recommendations - Revenue projections for 2025, 2026, and 2027 are estimated at 880 million, 1.02 billion, and 1.49 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [6][30]. - The company is still in the investment phase for innovative drug development, with projected net profits of -20 million, 10 million, and 280 million yuan for the same years [6][30].

Investment Rating - The report assigns a "Buy" rating for the company, Lepu Biopharma (2157.HK), marking its first coverage [1]. Core Insights - The company is entering a harvest period for new drug approvals, having established a comprehensive pipeline in oncology that includes immunotherapy, ADC (Antibody-Drug Conjugate) targeted therapy, and oncolytic virus drugs. The company has multiple ADC drugs and other therapies in clinical stages, with expectations for new drug approvals in the next 3-5 years [3][10]. - The ADC pipeline is characterized by unique features and competitive advantages in various indications, with MRG003 (EGFR ADC) already approved for NPC (nasopharyngeal carcinoma) in China and showing promising results in other indications [4][30]. - The introduction of oncolytic virus therapy CG0070 has shown potential in the bladder cancer market, with successful regulatory progress in the U.S. and ongoing clinical trials in China [5][30]. - Financially, the company has achieved its first profit and positive operating cash flow in the first half of 2025, with steady revenue growth driven by business development and sales [25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, with a pipeline that includes immunotherapy, ADCs, and oncolytic virus therapies. It has developed a robust ADC technology platform and has multiple products in various stages of clinical development [11][10]. - The pipeline includes 6 ADC drugs and 1 oncolytic virus therapy, with several candidates in pivotal clinical stages, indicating a well-structured development strategy [14][10]. Unique Features of ADCs - MRG003 has been approved for NPC and is in advanced trials for HNSCC (head and neck squamous cell carcinoma) and NSCLC (non-small cell lung cancer), showcasing its broad applicability and competitive edge [30][4]. - Other ADCs in development, such as MRG004A for pancreatic cancer and MRG006A for liver cancer, are also progressing well, with MRG004A entering pivotal trials [30][6]. Financial Performance and Projections - The company reported revenues of 4.66 billion yuan in the first half of 2025, a significant increase from 1.33 billion yuan in the same period of 2024. The net profit for the same period was 290 million yuan, marking a turnaround from a loss of 197 million yuan in the previous year [25][30]. - Revenue projections for 2025, 2026, and 2027 are estimated at 8.8 billion yuan, 10.2 billion yuan, and 14.9 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [30].

Investment Rating - The report maintains a "Recommended" rating for the companies involved in the chromatography industry, particularly focusing on domestic innovation and market potential [57]. Core Insights - The chromatography industry is experiencing significant growth, driven by the increasing demand in the biopharmaceutical sector, which accounts for 80% of the chromatography medium applications [22][37]. - The global biopharmaceutical market is projected to grow from approximately $503 billion in 2023 to $892 billion by 2028, with a compound annual growth rate (CAGR) of 9.5%-12.5% [30]. - Domestic biopharmaceutical market growth is robust, with projections indicating an increase from ¥262.2 billion in 2018 to ¥534.8 billion in 2024, reflecting a CAGR of 12.61% [37]. Market Overview - The chromatography industry includes core consumables, instruments, and software services, with a complete product system that plays a crucial role in drug purification and analysis [15][16]. - The chromatography equipment market is expected to see significant growth, with the small molecule liquid chromatography system market projected to grow from $3.6 billion in 2021 to $7.7 billion by 2026, representing a CAGR of 16.7% [40]. - The chromatography medium market in China is expected to grow from ¥112 billion in 2023 to over ¥203 billion by 2026, with a CAGR of 21.92% [47]. Key Segments - **Innovative Drugs**: The report highlights the transition from generic to innovative drugs in China, with a focus on companies like BeiGene and Innovent Biologics, which are expected to lead in product pipelines and market share [9][57]. - **Medical Devices**: The report notes a recovery in the bidding for imaging devices and a growing market for home medical devices, driven by government subsidies [61]. - **IVD (In Vitro Diagnostics)**: The report emphasizes the acceleration of domestic replacement in the luminescence sector, with companies like Mindray and New Industries leading the charge [59][60]. Industry Trends - The report identifies a shift towards domestic production and innovation in the chromatography sector, with local companies making significant strides in filling the gaps left by international firms [53][56]. - The biopharmaceutical sector's increasing reliance on chromatography technology for drug development and production is expected to drive demand for high-quality chromatography products [22][37]. - The report also discusses the impact of national policies aimed at promoting domestic high-end scientific instruments, which are expected to further enhance the growth of the chromatography industry [53].

Investment Rating - The report initiates coverage with an "Outperform" rating for Lepu Biopharma-B (2157) [4] Core Views - The company is a leading domestic innovative pharmaceutical enterprise focusing on ADC combined with IO in oncology, with expectations for rapid market penetration following the approval of MRG003 [1][4] - The product pipeline is expected to expand internationally, indicating strong long-term growth potential for the company [1] Financial Summary - Projected total revenue for 2024A, 2025E, 2026E, and 2027E is 368 million, 853 million, 1,204 million, and 1,665 million RMB respectively, reflecting growth rates of 63%, 132%, 41%, and 38% [3] - Gross profit is expected to increase from 292.97 million in 2024A to 1,415.20 million in 2027E, with a gross margin projected to be around 79.66% to 85% [3] - Net profit is forecasted to improve from -411 million in 2024A to -29 million in 2027E, indicating a significant reduction in losses [3] Company Overview - Lepu Biopharma was established in January 2018 and focuses on oncology, particularly targeted and immunotherapy [9] - The company has built a diverse product pipeline through acquisitions and partnerships, including PD-1 antibodies and ADCs [9] - The management team is experienced, with a high concentration of ownership, ensuring stability and strategic direction [13][15] Market Potential - The global and Chinese cancer immunotherapy market is expected to grow significantly, with a CAGR of 16.3% and 25.1% respectively from 2025 to 2030 [28][31] - The PD-1 therapy market in China is projected to reach 582 billion RMB by 2030, with a CAGR of 30.5% from 2020 to 2025 [33][35] ADC Market Growth - The global ADC market is anticipated to reach 66.2 billion USD by 2030, with a CAGR of 30.3% from 2023 to 2030 [41] - The ADC market in China is expected to grow at a CAGR of 72.6% from 2023 to 2028, reaching 38.3 billion RMB [44][45] Product Pipeline and Clinical Development - MRG003 is currently under NDA review and has shown promising results in clinical trials for R/M NPC, with a significant improvement in overall response rates compared to chemotherapy [56][61] - The company is actively exploring combination therapies with PD-1 inhibitors, which may enhance treatment efficacy [60][65]

Group 1: Market Strategy - The report emphasizes that external disturbances will not end the upward trend, and market adjustments present opportunities to increase holdings in Chinese assets [2][28] - The current market volatility is attributed to concerns over major power dynamics, but the report maintains a more optimistic outlook compared to consensus [28] - The report suggests that the current adjustment in the A-share technology sector is nearing historical averages, indicating potential for market structure improvement [28][30] Group 2: Earnings Insights - The report highlights the importance of the upcoming Q3 earnings reports, noting that performance during this period significantly impacts stock prices [30] - It identifies sectors with high earnings growth potential, particularly in the AI industry chain, equipment manufacturing, and certain resource sectors [30] Group 3: Industry Comparisons - The report asserts that there will be no style switch in investment focus, with emerging technology remaining the main line and cyclical finance as a dark horse [31] - It recommends focusing on sectors such as internet, semiconductor, defense, and robotics, as well as financial stocks like brokers and banks [31] Group 4: Company Focus - Lepu Biopharma - Lepu Biopharma is recognized as a leading domestic innovative drug company in the ADC combined IO layout, with expectations for rapid market penetration following the approval of MRG003 [10][12] - The company has a robust pipeline of oncology products covering immunotherapy, ADC targeted therapy, and oncolytic virus drugs, positioning it well for future growth [10][12]